EWTX Edgewise Therapeutics Inc

$14.62

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Edgewise Therapeutics Inc

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.

Website: https://edgewisetx.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1710072
Address
3415 COLORADO AVE., BOULDER, CO, US
Valuation
Market Cap
$1.41B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
3.08
Performance
EPS
$-1.45
Dividend Yield
—
Profit Margin
0.00%
ROE
-34.40%
Technicals
50D MA
$22.35
200D MA
$25.18
52W High
$38.12
52W Low
$10.60
Fundamentals
Shares Outstanding
105M
Target Price
$42.78
Beta
0.33

EWTX EPS Estimates vs Actual

● Estimated
● Actual

EWTX News & Sentiment

Aug 14, 2025 • Benzinga NEUTRAL
Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm - Edgewise Therapeutics ( NASDAQ:EWTX )
Investors can contact the law firm at no cost to learn more about recovering their losses
Jul 28, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - Edgewise Therapeutics ( NASDAQ:EWTX )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ( "Edgewise" or the "Company" ) EWTX. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Jul 23, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - Edgewise Therapeutics ( NASDAQ:EWTX )
NEW YORK, July 23, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ( "Edgewise" or the "Company" ) EWTX. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Jul 03, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX - Edgewise Therapeutics ( NASDAQ:EWTX )
NEW YORK, July 03, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ( "Edgewise" or the "Company" ) EWTX. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Jun 30, 2025 • Benzinga SOMEWHAT-BULLISH
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Aytu BioPharma ( NASDAQ:AYTU ) , Circle Internet Group ( NYSE:CRCL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ascendiant Capital analyst Edward Woo initiated coverage on Aytu BioPharma, Inc.
Jun 26, 2025 • Benzinga SOMEWHAT-BULLISH
No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall - Edgewise Therapeutics ( NASDAQ:EWTX )
99% of eligible Becker participants ( n=85 ) enrolled in MESA showed stable or improved NSAA scores after 18 months. Sevasemten was well tolerated in Phase 2 Duchenne studies; 10 mg dose selected for Phase 3. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news ...
Sentiment Snapshot

Average Sentiment Score:

0.242
50 articles with scored sentiment

Overall Sentiment:

Bullish

EWTX Reported Earnings

Feb 20, 2025
Dec 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.42
  • Estimate: $-0.42
  • Whisper: —
  • Surprise %: 0.5%
Nov 07, 2024
Sep 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.36
  • Estimate: $-0.37
  • Whisper: —
  • Surprise %: 2.7%
Aug 08, 2024
Jun 30, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.34
  • Estimate: $-0.34
  • Whisper: —
  • Surprise %: 0.0%
May 09, 2024
Mar 31, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $-0.33
  • Estimate: $-0.39
  • Whisper: —
  • Surprise %: 15.4%
Feb 22, 2024
Dec 31, 2023 (Pre market)
-0.04 Surprise
  • Reported EPS: $-0.47
  • Estimate: $-0.43
  • Whisper: —
  • Surprise %: -9.3%
Nov 09, 2023
Sep 30, 2023 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.41
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: -2.5%
Aug 10, 2023
Jun 30, 2023 (Pre market)
0.06 Surprise
  • Reported EPS: $-0.34
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: 15.0%
May 11, 2023
Mar 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.36
  • Estimate: $-0.36
  • Whisper: —
  • Surprise %: 0.0%
Feb 23, 2023
Dec 31, 2022 (Pre market)
0.03 Surprise
  • Reported EPS: $-0.31
  • Estimate: $-0.34
  • Whisper: —
  • Surprise %: 8.8%

Financials